Biotie

Turku, Finland Founded: 1998 • Age: 28 yrs Acquired By Acorda
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie.
Request Access

About Biotie

Biotie is a company based in Turku (Finland) founded in 1998 was acquired by Acorda in January 2016.. Biotie has raised $149.81 million across 4 funding rounds from investors including Acorda and The Baupost Group. The company has 27 employees as of December 31, 2022. Biotie has completed 2 acquisitions, including Elbion and Synosia Therapeutics. Biotie operates in a competitive market with competitors including Indivior, Ethypharm, Braeburn, Amygdala Neurosciences and Cessation Therapeutics, among others.

  • Headquarter Turku, Finland
  • Employees 27 as on 31 Dec, 2022
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $149.81 M (USD)

    in 4 rounds

  • Latest Funding Round
  • Investors
    Acorda

    & 1 more

  • Employee Count
    27

    as on Dec 31, 2022

  • Investments & Acquisitions
    Elbion

    & 1 more

  • Acquired by
    Acorda

    (Jan 19, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Biotie

Biotie has successfully raised a total of $149.81M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 4
  • Last Round
  • First Round

    (11 Jun 2013)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2015 Amount Post-IPO - Biotie Valuation

investors

May, 2015 Amount Series D - Biotie Valuation

investors

Jul, 2014 Amount Grant - Biotie Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Biotie

Biotie has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Acorda and The Baupost Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Conducts long-term value-oriented investments for families, foundations, and institutions.
Founded Year Domain Location
Engaged in the development and commercialization of therapies that improve neurological function.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Biotie

Biotie has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Elbion and Synosia Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Therapeutics for CNS disorders including Parkinson's are developed.
2005
Small molecules for CNS and inflammatory diseases were discovered.
2002
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Biotie

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Biotie Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Biotie

Biotie operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Ethypharm, Braeburn, Amygdala Neurosciences and Cessation Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for opioid addiction treatment are developed and commercialized.
domain founded_year HQ Location
Therapies for pain and addiction treatment are developed.
domain founded_year HQ Location
Long-acting therapies for opioid addiction and chronic pain are developed.
domain founded_year HQ Location
Therapies for substance use disorders are developed by Amygdala Neurosciences.
domain founded_year HQ Location
Developer of immunotherapy based vaccines to manage addictions
domain founded_year HQ Location
Developer of small molecule drugs targeting CB1 receptor for CNS diseases
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Biotie

When was Biotie founded?

Biotie was founded in 1998 and raised its 1st funding round 15 years after it was founded.

Where is Biotie located?

Biotie is headquartered in Turku, Finland. It is registered at Turku, Varsinais-suomi, Finland.

Who is the current CEO of Biotie?

Jari Saarinen is the current CEO of Biotie.

Is Biotie a funded company?

Biotie is a funded company, having raised a total of $149.81M across 4 funding rounds to date. The company's 1st funding round was a Grant of $2M, raised on Jun 11, 2013.

How many employees does Biotie have?

As of Dec 31, 2022, the latest employee count at Biotie is 27.

What does Biotie do?

Biotie was founded in 1998 in Turku, Finland, as a biotech firm specializing in drug development for central nervous system disorders. Operations center on advancing treatments for neurodegenerative and psychiatric conditions, including Selincro for alcohol dependency, which is marketed in Europe by H. Lundbeck AS, and Tozadenant, now entering Phase 3 trials for Parkinsons disease. The company operates in the commercial stage of biotechnology.

Who are the top competitors of Biotie?

Biotie's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.

How many acquisitions has Biotie made?

Biotie has made 2 acquisitions, including Elbion, and Synosia Therapeutics.

Who are Biotie's investors?

Biotie has 2 investors. Key investors include Acorda, and The Baupost Group.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available